Back to top
more

Alnylam Pharmaceuticals (ALNY)

(Delayed Data from NSDQ)

$143.31 USD

143.31
479,138

-0.40 (-0.28%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $143.37 +0.06 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ALNY

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Alnylam Pharmaceuticals, Inc. [ALNY]

Reports for Purchase

Showing records 381 - 400 ( 406 total )

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 381

11/04/2010

Company Report

Pages: 3

With focus now 100% on internal pipeline, Reports 3Q10; expecting liver cancer data next week.

Provider: RODMAN & RENSHAW, CO.

Analyst: SIMEONIDIS S

Price: 10.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 382

10/12/2010

Daily Note

Pages: 7

MORNING SUMMARY

Provider: RODMAN & RENSHAW, CO.

Price: 25.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 383

10/11/2010

Industry Report

Pages: 3

Life Sciences - R&R’s Week in Review: Oncology and Stem Cell Sectors

Provider: RODMAN & RENSHAW, CO.

Analyst: BENJAMIN R

Price: 10.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 384

09/24/2010

Company Report

Pages: 3

Novartis passes on option to Alnylam license; days of $100M upfront for platform licenses

Provider: RODMAN & RENSHAW, CO.

Analyst: SIMEONIDIS S

Price: 10.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 385

09/08/2010

Company Report

Pages: 7

Price: 24.95

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 386

08/05/2010

Daily Note

Pages: 9

MORNING SUMMARY

Provider: RODMAN & RENSHAW, CO.

Price: 25.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 387

08/04/2010

Company Report

Pages: 3

No major updates on 2Q10 call; Novartis decision on $100M adoption license next major milestone

Provider: RODMAN & RENSHAW, CO.

Analyst: SIMEONIDIS S

Price: 10.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 388

07/08/2010

Daily Note

Pages: 5

MORNING SUMMARY

Provider: RODMAN & RENSHAW, CO.

Price: 10.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 389

07/07/2010

Daily Note

Pages: 3

Continues to move its siRNAs into the clinic.

Provider: RODMAN & RENSHAW, CO.

Analyst: SIMEONIDIS S

Price: 10.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 390

06/29/2010

Daily Note

Pages: 8

MORNING SUMMARY

Provider: RODMAN & RENSHAW, CO.

Analyst: BENJAMIN R

Price: 25.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 391

06/28/2010

Industry Report

Pages: 3

R&R’s Week in Review: Oncology and Stem Cell Sectors

Provider: RODMAN & RENSHAW, CO.

Analyst: BENJAMIN R

Price: 10.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 392

06/14/2010

Industry Report

Pages: 3

R&R’s Week in Review: Oncology and Stem Cell Sectors

Provider: RODMAN & RENSHAW, CO.

Analyst: BENJAMIN R

Price: 10.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 393

06/07/2010

Company Report

Pages: 7

Price: 24.95

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 394

06/02/2010

Industry Report

Pages: 4

2010 ASCO Preview & Abstract / Event Planner.

Provider: RODMAN & RENSHAW, CO.

Analyst: BENJAMIN R

Price: 10.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 395

05/06/2010

Industry Report

Pages: 5

BIOTECH 2010 AND BEYOND

Provider: RODMAN & RENSHAW, CO.

Analyst: BENJAMIN R

Price: 10.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 396

05/06/2010

Daily Note

Pages: 7

MORNING SUMMARY

Provider: RODMAN & RENSHAW, CO.

Price: 25.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 397

05/05/2010

Company Report

Pages: 3

Reports 1Q10 results

Provider: RODMAN & RENSHAW, CO.

Analyst: SIMEONIDIS S

Price: 10.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 398

04/13/2010

Company Report

Pages: 7

Price: 24.95

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 399

04/07/2010

Daily Note

Pages: 3

Another day, another brick on Alnylam''s IP wall; early, broad, fundamental RNAi patent allowed

Provider: RODMAN & RENSHAW, CO.

Analyst: SIMEONIDIS S

Price: 10.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 400

03/31/2010

Daily Note

Pages: 3

Alnylam continues to extend its dominance in RNAi IP: additional Tuschl II patent granted

Provider: RODMAN & RENSHAW, CO.

Analyst: SIMEONIDIS S

Price: 10.00

Research Provided by a Third Party